Brain & Breakfast: Impacts of the European HTA regulation in Norway

PharmaLex (a part of Cencora) and The Life Science Cluster are pleased to invite you to a Brain & Breakfast event on the 27th of February in Oslo focusing on the European HTA regulation.

Europe is implementing a new HTA regulation! Potential impact for Pharma/Biotech companies in a fast-changing environment.

When: 27 February 2025
Time: 8.30–10.00
Where: Oslo Science Park 

REGISTER HERE

Healthcare in Europe prepares for the EU HTA. Join us for an insightful morning as we explore the transformative effects of the EU HTA regulation on Norway´s healthcare system. This exclusive event is tailored for life science professionals who are eager to understand the challenges and opportunities this new framework brings.

You don’t want to miss:
• Fresh insights into how other countries have reformed their HTA processes
• Impact of these reforms on healthcare access, innovation, and pricing
• Strategies to align national systems with EU regulations
• How the new HTA regulation impact patient access for your products

           

Speakers:

  • Herbert Altmann, VP Market Access & Healthcare Consulting Europe, PharmaLex
  • Matias Olsen, Senior Manager, Public Affairs & Policy at European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Gain valuable insights from industry leaders, network with peers, and discover how the EU HTA can shape the future of healthcare innovation in Norway.
Spaces are limited, so secure your spot today!

REGISTER HERE

The EU Health Technology Assessment (HTA) Regulation, set to take effect in January 2025, marks a significant shift in healthcare evaluation within the European Union. This regulation aims to streamline collaboration on health technology assessments across EU member states, fostering a more unified approach to evaluating medical technologies and therapies.

 

 

Related Events

Scroll to Top